Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
Authors: Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L. McAfee, Andrew M. Brunner, Philip C. Amrein, Alice S. Mims, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Dylan M. Marchione, Vincent T. Ho, Yi-Bin Chen
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4379013108